Clinical Trials
70 trialsStudy of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Hoosier Cancer Research Network
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
Tianjin Medical University Cancer Institute and Hospital
Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases
Tianjin Medical University Cancer Institute and Hospital
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Eastern Cooperative Oncology Group
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study
Ningbo Medical Center Lihuili Hospital
Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer
Guangdong Provincial People's Hospital
LyRICX
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
University of Wisconsin, Madison
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Georgetown University
Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ImmunityBio, Inc.
Folfox+Irinotecan+Chemort In Esophageal Cancer
Massachusetts General Hospital
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Sun Yat-sen University
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
St. Jude Children's Research Hospital
A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer
Fudan University
Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer
The First Affiliated Hospital of Zhengzhou University
FUNGEMAX
Federation Francophone de Cancerologie Digestive
PANORAMIX
GERCOR - Multidisciplinary Oncology Cooperative Group
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
Sun Yat-sen University
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
West China Hospital
Phenomenal
MedSIR
Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
Big Ten Cancer Research Consortium
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
Hebei Medical University Fourth Hospital
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Roswell Park Cancer Institute
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
Affiliated Hospital of Nantong University
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Sun Yat-sen University
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
OESIRI
Federation Francophone de Cancerologie Digestive
NET02
The Christie NHS Foundation Trust
LIAES
Second Affiliated Hospital, School of Medicine, Zhejiang University
Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Akeso
Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
Sun Yat-sen University
Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer
Ruijin Hospital
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
Hebei Medical University Fourth Hospital
COMBAT
BioLineRx, Ltd.
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
West China Hospital
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
Fudan University
Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer
Servier
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Bristol-Myers Squibb
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)
CSPC Ouyi Pharmaceutical Co., Ltd.
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC
Zhejiang Cancer Hospital
NALIRIFOX as Induction Therapy in LAPC
The First Affiliated Hospital with Nanjing Medical University